

PAUL HASTINGS

Home > Professionals > Evan D. Diamond



EVAN D. DIAMOND

Associate, Litigation Department

New York

T 1(212) 318-6004

F 1(212) 230-5104

evandiamond@paulhastings.com

[Download VCard](#) | [Download PDF](#)

PRACTICE AREAS

Litigation
Life Sciences
Patent Office
Patent Litigation
Intellectual Property

ADMISSIONS

New York Bar

EDUCATION

Harvard Law School,
J.D., 2007
University of
Pennsylvania, B.A.,
2004
University of
Pennsylvania, M.S.,
2004

NEWS

Paul Hastings Achieves
First Ever Win in New
Form of IP Proceeding
for Pharmaceutical
Company
December 11, 2014

INSIGHTS

Paul Hastings Wins for
Galderma and Supernus
in First Hatch-Waxman
Inter Partes Reviews to
Reach Final Written
Decision
December 10, 2014

Evan D. Diamond is an associate in the Life Sciences Intellectual Property practice of Paul Hastings. Mr. Diamond's practice focuses on patent litigation matters in the fields of pharmaceuticals and biotechnology. Mr. Diamond has represented clients in federal district court litigations, in appeal proceedings before the Federal Circuit, and in inter partes review proceedings before the Patent Trials and Appeals Board. In addition, Mr. Diamond has provided strategic counseling to clients regarding potential litigation and other patent-related matters.

Experience

Galderma Laboratories, L.P. and Supernus

Pharmaceuticals, Inc.: Patent infringement litigation relating to the rosacea treatment Oracea®. Successfully upheld validity of longest-running patent covering Oracea® in federal district court, followed by a per curiam affirmance by the Federal Circuit. Successfully obtained preliminary injunction precluding generic launch prior to patent expiration. Continued to defend against subsequent challenges to patents covering Oracea® in federal district court and in inter partes review proceedings.

Eisai Inc.: Patent infringement litigation regarding Targretin®, a treatment for cutaneous T-cell lymphoma.

Forest Laboratories, Inc. and Merz Pharmaceuticals

GmbH: Patent infringement litigation relating to Alzheimer's disease treatment Namenda®.

Forest Laboratories, Inc. and H. Lundbeck A/S: Patent infringement litigation concerning the multi-billion dollar drug product Lexapro®, a selective serotonin reuptake inhibitor indicated for the treatment of depression and anxiety.

FDA Issues Draft Guidance on Reference Product Exclusivity for Biologics

August 07, 2014

Accolades and Recognitions

Financial Times, U.S. Innovative Lawyers 2012: top "Standout" rating in Intellectual Property awarded to Paul Hastings for representation of Galderma in Oracea® litigation

Law360, Life Sciences Group of the Year (2013), awarded to Paul Hastings for representations including Galderma in Oracea® litigation

Honorable Mention, H. Thomas Austern Memorial Writing Competition, Food and Drug Law Institute (2008)

Paul Hastings Wins Federal Circuit Affirmance Upholding Key Patent Covering Once-Daily Formulation for ORACEA

August 09, 2013

[Read More \[+/-\]](#)

RANKINGS & AWARDS

Legal Media Group's 2013 LMG Life Science Awards

The firm was nominated as a 2013 LMG Life Science nominee in the "Litigation Team of the Year" and "(General) Patent Litigation: Firm of the Year" categories.

August 12, 2013

Speaking Engagements and Publications

Panelist, "Predictions Related to Biosimilars Challenges" (NewYorkBIO Conference, May 2014)

E. Diamond, "Reverse-FOIA Limitations on Agency Actions to Disclose Human Gene Therapy Clinical Data," 63 Food & Drug L. J. 321 (2008)

G.S. Pesiridis, E. Diamond, and G.D. Van Duyne, "Role of pICln in Methylation of Sm Proteins by PRMT5," J. Biol. Chem. (2009) 284:21347-21359

Education

Harvard Law School, J.D. (*cum laude*), 2007

University of Pennsylvania, B.A. in Biochemistry (*summa cum laude*, Phi Beta Kappa), 2004

University of Pennsylvania, M.S. in Chemistry, 2004



Intellectual Property Magazine

Intellectual Property Magazine recognized Paul Hastings' IP Pharmaceutical Team as the *Pharmaceutical Team of the Year*.

November 30, 2010